Alliance Pharma PLC Hardman Research: Strong Operational Cashflow
January 29 2018 - 5:20AM
RNS Non-Regulatory
TIDMAPH
Alliance Pharma PLC
29 January 2018
Hardman Research: Strong Operational Cashflow
2017: strong operational cashflow - Alliance Pharma is
continuing with its buy-and-build strategy having evolved through
35 acquisitions over a period of 20 years into a profitable,
cash-generative, specialty pharma business. The company has a mix
of international growth brands - notably Kelo-Cote and MacuShield -
and a bedrock of solid local low-growth brands. In a trading
statement for 2017, strong sales of its international growth brands
have underpinned group sales growth and helped generate strong
underlying operational cashflow. The recent acquisitions of
Vamousse (third international growth brand) and Ametop (bedrock
brand) look set to further enhance future performance.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/29-01-18-alliance-pharma.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea www.hardmanandco.com
EC2M 1NH Hill
Follow us on Twitter Dr Gregoire
@HardmanandCo Pave
+44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFLLLTIAFIT
(END) Dow Jones Newswires
January 29, 2018 06:20 ET (11:20 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024